Physician profile
Srikanth Nagalla
NPI 1902068778
$638,795.38
in general payments reported to CMS, 2019-2025
30 companies · $101K in 2025
The $101K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $36K · 2021: $81K · 2022: $140K · 2023: $129K · 2024: $137K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $169K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $141K · Travel and Lodging: $41K · Honoraria: $9,670 · Food and Beverage: $6,317 · Education: $48.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $169,330.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $141,173.26 |
| Travel and Lodging | $41,141.99 |
| Honoraria | $9,670.00 |
| Food and Beverage | $6,316.77 |
| Education | $48.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $279,354.24 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $140,547.10 | 2020-2025 | |
| Dova Pharmaceuticals | $62,513.64 | 2020-2021 | |
| Sobi, INC | $59,776.87 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $37,572.23 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Agios Pharmaceuticals, INC. | $23,346.36 | 2022-2025 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $13,222.03 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $6,959.45 | 2022-2025 | Empaveli |
| Biomarin Pharmaceutical INC. | $4,694.07 | 2020 | |
| Janssen Scientific Affairs, LLC | $3,986.88 | 2025 | |
| Kedrion Biopharma INC. | $2,634.00 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $2,202.50 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $482.70 | 2022-2025 | Monoferric |
| Novartis Pharmaceuticals Corporation | $283.24 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $237.10 | 2021-2024 | Reblozyl |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $172.46 | 2022-2025 | Jakafi |
| Pharmaessentia USA Corporation | $154.45 | 2024-2025 | Besremi |
| Merck Sharp & Dohme LLC | $112.30 | 2023-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $112.19 | 2025 | Enhertu |
| Recordati_rare_diseases_inc. | $80.11 | 2024 | Sylvant |
| Argenx US, INC. | $77.84 | 2023 | |
| Daiichi Sankyo INC. | $56.37 | 2024-2025 | Injectafer |
| Lilly USA, LLC | $46.15 | 2023-2024 | Verzenio, Jaypirca |
| Blueprint Medicines Corporation | $27.89 | 2025 | Ayvakit |
| Taiho Oncology, INC. | $27.78 | 2025 | |
| Seagen INC. | $27.42 | 2023 | Tukysa |
| Geron Corporation | $25.38 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $22.86 | 2023 | Vonvendi |
| Global Blood Therapeutics, INC. | $20.82 | 2022 | |
| Springworks Therapeutics, INC. | $18.95 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Nagalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.